|
|
|
Volumn 3, Issue 1, 2004, Pages 54-61
|
|
Treatment options for newly diagnosed patients with chronic myeloid leukemia.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALKYLATING AGENT;
ANTINEOPLASTIC AGENT;
BCR ABL PROTEIN;
ENZYME INHIBITOR;
IMATINIB;
PIPERAZINE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
BLOOD;
BONE MARROW TRANSPLANTATION;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG ANTAGONISM;
DRUG RESISTANCE;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMAN;
MULTICENTER STUDY;
MULTIMODALITY CANCER THERAPY;
MYELOID LEUKEMIA;
PROGNOSIS;
REVIEW;
SURVIVAL RATE;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC AGENTS, ALKYLATING;
BONE MARROW TRANSPLANTATION;
CLINICAL TRIALS;
COMBINED MODALITY THERAPY;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG RESISTANCE, NEOPLASM;
ENZYME INHIBITORS;
FUSION PROTEINS, BCR-ABL;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE;
MULTICENTER STUDIES;
PIPERAZINES;
PROGNOSIS;
PYRIMIDINES;
SURVIVAL RATE;
TREATMENT OUTCOME;
|
|
EID: 2442438015
PISSN: 15403408
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (8)
|
|
References (50)
|
